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BACKGROUND
Coronavirus disease 2019 (Covid-19) is associated with diffuse lung damage. Gluco-
corticoids may modulate inflammation-mediated lung injury and thereby reduce 
progression to respiratory failure and death.
METHODS
In this controlled, open-label trial comparing a range of possible treatments 
in patients who were hospitalized with Covid-19, we randomly assigned patients to 
receive oral or intravenous dexamethasone (at a dose of 6 mg once daily) for up 
to 10 days or to receive usual care alone. The primary outcome was 28-day mortality. 
Here, we report the final results of this assessment.
RESULTS
A total of 2104 patients were assigned to receive dexamethasone and 4321 to re-
ceive usual care. Overall, 482 patients (22.9%) in the dexamethasone group and 
1110 patients (25.7%) in the usual care group died within 28 days after randomiza-
tion (age-adjusted rate ratio, 0.83; 95% confidence interval [CI], 0.75 to 0.93; 
P<0.001). The proportional and absolute between-group differences in mortality 
varied considerably according to the level of respiratory support that the patients 
were receiving at the time of randomization. In the dexamethasone group, the 
incidence of death was lower than that in the usual care group among patients 
receiving invasive mechanical ventilation (29.3% vs. 41.4%; rate ratio, 0.64; 95% 
CI, 0.51 to 0.81) and among those receiving oxygen without invasive mechanical 
ventilation (23.3% vs. 26.2%; rate ratio, 0.82; 95% CI, 0.72 to 0.94) but not among 
those who were receiving no respiratory support at randomization (17.8% vs. 14.0%; 
rate ratio, 1.19; 95% CI, 0.92 to 1.55).
CONCLUSIONS
In patients hospitalized with Covid-19, the use of dexamethasone resulted in 
lower 28-day mortality among those who were receiving either invasive mechanical 
ventilation or oxygen alone at randomization but not among those receiving no 
respiratory support. (Funded by the Medical Research Council and National In-
stitute for Health Research and others; RECOVERY ClinicalTrials.gov number, 
NCT04381936; ISRCTN number, 50189673.)
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Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the cause of coronavirus disease 2019 (Covid-19), emerged 
in China in late 2019 from a zoonotic source.1 
The majority of Covid-19 cases either are asymp-
tomatic or result in only mild disease. However, 
in a substantial percentage of patients, a respira-
tory illness requiring hospital care develops,2 
and such infections can progress to critical ill-
ness with hypoxemic respiratory failure requir-
ing prolonged ventilatory support.3-6 Among pa-
tients with Covid-19 who were admitted to 
hospitals in the United Kingdom in the first half 
of 2020, the case fatality rate was approximately 
26% overall and more than 37% among patients 
who were undergoing invasive mechanical venti-
lation.7 Although remdesivir has been shown to 
shorten the time until recovery in hospitalized 
patients,8 no therapeutic agents have been shown 
to reduce mortality.
The pathophysiological features of severe 
Covid-19 are dominated by an acute pneumonic 
process with extensive radiologic opacity and, on 
autopsy, diffuse alveolar damage, inflammatory 
infiltrates, and microvascular thrombosis.9 In 
other severe viral pneumonias, such as highly 
pathogenic avian influenza,10 SARS,11 and pan-
demic and seasonal influenza,12 the host im-
mune response is thought to play a key role in 
the pathophysiology of organ failure. Inflamma-
tory organ injury may occur in severe Covid-19, 
with a subgroup of patients having markedly 
elevated levels of inflammatory markers, includ-
ing C-reactive protein, ferritin, interleukin-1, and 
interleukin-6.6,13,14 Several therapeutic interven-
tions have been proposed to mitigate inflamma-
tory organ injury in viral pneumonia, but the value 
of glucocorticoids has been widely debated.15,16
Although one small trial has reported im-
proved clinical outcomes in patients with Covid-19 
who were given methylprednisolone,17 the absence 
of reliable evidence from large-scale randomized 
clinical trials means there is uncertainty about 
the effectiveness of glucocorticoids in patients with 
Covid-19. Many guidelines for the treatment of 
such patients have stated that glucocorticoids were 
either contraindicated or not recommended,18 
although in China, glucocorticoids have been 
recommended for severe cases.19 However, in the 
first 6 months of the pandemic, practice varied 
widely across the world: in some series, as many 
as 50% of patients were treated with glucocorti-
coids.20,21 Here, we report the results of the con-
trolled, open-label Randomized Evaluation of 
Covid-19 Therapy (RECOVERY) trial of dexameth-
asone in patients hospitalized with Covid-19.
Me thods
Trial Design and Oversight
The RECOVERY trial was designed to evaluate 
the effects of potential treatments in patients 
hospitalized with Covid-19 at 176 National Health 
Service organizations in the United Kingdom 
and was supported by the National Institute for 
Health Research Clinical Research Network. 
(Details regarding this trial are provided in the 
Supplementary Appendix, available with the full 
text of this article at NEJM.org.) The trial is be-
ing coordinated by the Nuffield Department of 
Population Health at the University of Oxford, 
the trial sponsor. Although the randomization of 
patients to receive dexamethasone, hydroxychlo-
roquine, lopinavir–ritonavir, azithromycin, con-
valescent plasma, or tocilizumab has now been 
stopped, the trial continues randomization to 
other treatments, including REGN-COV2 (a com-
bination of two monoclonal antibodies directed 
against the SARS-CoV-2 spike protein), aspirin, 
colchicine, or usual care alone.
Hospitalized patients were eligible for the trial 
if they had clinically suspected or laboratory-
confirmed SARS-CoV-2 infection and no medical 
history that might, in the opinion of the attend-
ing clinician, put patients at substantial risk if 
they were to participate in the trial. Initially, re-
cruitment was limited to patients who were at 
least 18 years of age, but the age limit was re-
moved starting on May 9, 2020. Pregnant or 
breast-feeding women were eligible.
Written informed consent was obtained from 
all the patients or from a legal representative if 
they were unable to provide consent. The trial 
was conducted in accordance with the principles 
of the Good Clinical Practice guidelines of the 
International Conference on Harmonisation and 
was approved by the U.K. Medicines and Health-
care Products Regulatory Agency and the Cam-
bridge East Research Ethics Committee. The 
protocol with its statistical analysis plan is avail-
able at NEJM.org and on the trial website at 
www.recoverytrial.net.
A Quick Take 
is available at 
NEJM.org
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The initial version of the manuscript was 
drafted by the first and last authors, developed 
by the writing committee, and approved by all 
members of the trial steering committee. The 
funders had no role in the analysis of the data, 
in the preparation or approval of the manu-
script, or in the decision to submit the manu-
script for publication. The first and last mem-
bers of the writing committee vouch for the 
completeness and accuracy of the data and for 
the fidelity of the trial to the protocol and sta-
tistical analysis plan.
Randomization
We collected baseline data using a Web-based 
case-report form that included demographic data, 
the level of respiratory support, major coexisting 
illnesses, suitability of the trial treatment for a 
particular patient, and treatment availability at 
the trial site. Randomization was performed 
with the use of a Web-based system with con-
cealment of the trial-group assignment. Eligible 
and consenting patients were assigned in a 2:1 
ratio to receive either the usual standard of care 
alone or the usual standard of care plus oral or 
intravenous dexamethasone (at a dose of 6 mg 
once daily) for up to 10 days (or until hospital 
discharge if sooner) or to receive one of the 
other suitable and available treatments that were 
being evaluated in the trial.
For some patients, dexamethasone was unavail-
able at the hospital at the time of enrollment or 
was considered by the managing physician to be 
either definitely indicated or definitely contrain-
dicated. These patients were excluded from the 
randomized comparison between dexamethasone 
and usual care. The randomly assigned treat-
ment was prescribed by the treating clinician. 
Patients and local members of the trial staff 
were aware of the assigned treatments.
Procedures
A single online follow-up form was to be com-
pleted by the local trial staff when each patient 
was discharged or had died or at 28 days after 
randomization, whichever occurred first. Infor-
mation was recorded regarding the patients’ 
adherence to the assigned treatment, receipt of 
other treatments for Covid-19, duration of ad-
mission, receipt of respiratory support (with 
duration and type), receipt of renal dialysis or 
hemofiltration, and vital status (including the 
cause of death). In addition, we obtained routine 
health care and registry data, including informa-
tion on vital status (with date and cause of 
death), discharge from the hospital, and respira-
tory and renal support therapy.
Outcome Measures
The primary outcome was all-cause mortality 
within 28 days after randomization; further 
analyses were specified at 6 months. Secondary 
outcomes were the time until discharge from the 
hospital and, among patients not receiving inva-
sive mechanical ventilation at the time of ran-
domization, subsequent receipt of invasive me-
chanical ventilation (including extracorporeal 
membrane oxygenation) or death. Other prespeci-
fied clinical outcomes included cause-specific 
mortality, receipt of renal dialysis or hemofiltra-
tion, major cardiac arrhythmia (recorded in a 
subgroup), and receipt and duration of ventila-
tion. Among those receiving invasive mechanical 
ventilation at the time of randomization, the 
outcome of successful cessation of invasive me-
chanical ventilation was defined as cessation 
within (and survival to) 28 days. All information 
presented in this report is based on a data cutoff 
of December 14, 2020. Information regarding the 
primary and secondary outcomes is complete for 
99.9% of trial participants.
Statistical Analysis
As stated in the protocol, appropriate sample 
sizes could not be estimated when the trial was 
being planned at the start of the Covid-19 pan-
demic. As the trial progressed, the trial steering 
committee, whose members were unaware of the 
results of the trial comparisons, determined that 
if 28-day mortality was 20%, then the enroll-
ment of at least 2000 patients in the dexametha-
sone group and 4000 in the usual care group 
would provide a power of at least 90% at a two-
sided P value of 0.01 to detect a clinically rele-
vant proportional reduction of 20% (an abso-
lute difference of 4 percentage points) between 
the two groups. Consequently, on June 8, 2020, 
the steering committee closed recruitment to the 
dexamethasone group, since enrollment had ex-
ceeded 2000 patients.
For the primary outcome of 28-day mortality, 
the hazard ratio from Cox regression was used 
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to estimate the mortality rate ratio. Kaplan–
Meier survival curves were constructed to show 
cumulative mortality over the 28-day period. Cox 
regression was also used to analyze the second-
ary outcome of hospital discharge within 28 days 
and the outcome of successful cessation of inva-
sive mechanical ventilation. For both of these 
outcomes, data for patients who had died during 
hospitalization were censored on day 29. For the 
prespecified composite secondary outcome of 
invasive mechanical ventilation or death within 
28 days (among patients who were not receiving 
invasive mechanical ventilation at randomiza-
tion), the precise date of invasive mechanical 
ventilation was not available, so a log-binomial 
regression model was used to estimate the risk 
ratio. Risk ratios were also estimated for the 
outcomes of receipt of noninvasive or invasive 
mechanical ventilation (among patients who were 
not receiving oxygen or invasive mechanical ven-
tilation at the time of randomization) and re-
ceipt of renal-replacement therapy (among those 
not receiving such therapy at the time of ran-
domization).
Through the play of chance in the unstrati-
fied randomization, the mean age was 1.1 years 
older among patients in the dexamethasone 
group than among those in the usual care group 
(Table 1). To account for this imbalance in an 
important prognostic factor, estimates of rate 
and risk ratios were adjusted for the baseline age 
in three categories (<70 years, 70 to 79 years, 
and ≥80 years). This adjustment was not speci-
fied in the first version of the statistical analysis 
plan but was added once the imbalance in age 
became apparent. Results without age adjust-
ment (corresponding to the first version of the 
analysis plan) are provided in the Supplementary 
Appendix.
Prespecified analyses of the primary outcome 
were performed in six subgroups, as defined by 
characteristics at randomization: age, sex, race, 
level of respiratory support, days since symptom 
onset, and predicted 28-day mortality risk. In 
prespecified subgroups, we estimated rate ratios 
(or risk ratios in some analyses) and their confi-
dence intervals using regression models that 
included an interaction term between the treat-
ment assignment and the subgroup of interest. 
Chi-square tests for heterogeneity or linear trend 
across the subgroup-specific log estimates were 
then performed in accordance with the pre-
specified plan.
All P values are two-sided and are shown 
without adjustment for multiple testing. All 
analyses were performed according to the inten-
tion-to-treat principle. The full database is held 
by the trial team, which collected the data from 
trial sites and performed the analyses at the 




Of the 11,303 patients who underwent random-
ization from March 19 to June 8, 2020, a total of 
9355 (83%) were eligible to receive dexametha-
sone (i.e., the drug was available in the hospital 
at the time and the patient had no known indica-
tion for or contraindication to dexamethasone). 
Of these patients, 6425 underwent randomiza-
tion to receive either dexamethasone (2104 pa-
tients) or usual care alone (4321 patients) (Fig. 1). 
The remaining patients were randomly assigned 
to one of the other treatment groups being evalu-
ated in the trial.
The mean (±SD) age of the patients in this 
comparison was 66.1±15.7 years, 36% of the pa-
tients were female, and 18% were Black, Asian, or 
from a minority ethnic group (Table 1 and Table 
S1 in the Supplementary Appendix). A history of 
diabetes was present in 24% of the patients, 
heart disease in 27%, and chronic lung disease 
in 21%, with 56% having at least one major co-
existing illness recorded. In this analysis, 89% 
of the patients had laboratory-confirmed SARS-
CoV-2 infection. At randomization, 16% were 
receiving invasive mechanical ventilation or extra-
corporeal membrane oxygenation, 60% were re-
ceiving oxygen only (with or without noninvasive 
ventilation), and 24% were receiving neither.
In the dexamethasone group, 95% of the pa-
tients received at least one dose of a glucocorti-
coid (Table S2). The median duration of treat-
ment was 7 days (interquartile range, 3 to 10). In 
the usual care group, 8% of the patients received 
a glucocorticoid as part of their clinical care. 
The use of azithromycin or another macrolide 
antibiotic during the follow-up period was simi-
lar in the dexamethasone group and the usual 
care group (24% vs. 26%), and 0 to 3% of patients 
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Table 1. Characteristics of the Patients at Baseline, According to Treatment Assignment and Level of Respiratory Support.*
Characteristic Treatment Assignment
















Mean — yr 66.9±15.4 65.8±15.8 69.4±17.5 66.7±15.3 59.1±11.4
Distribution — no. (%)
<70 yr 1141 (54) 2505 (58) 659 (43) 2149 (55) 838 (83)
70 to 79 yr 469 (22) 859 (20) 338 (22) 837 (22) 153 (15)
≥80 yr 494 (23) 957 (22) 538 (35) 897 (23) 16 (2)
Sex — no. (%)
Male 1338 (64) 2749 (64) 891 (58) 2462 (63) 734 (73)
Female‡ 766 (36) 1572 (36) 644 (42) 1421 (37) 273 (27)
Race or ethnic group — no. (%)§
White 1550 (74) 3139 (73) 1221 (80) 2894 (75) 574 (57)
Black, Asian, or minority ethnic 
group
364 (17) 783 (18) 191 (12) 662 (17) 294 (29)
Unknown 190 (9) 399 (9) 123 (8) 327 (8) 139 (14)
Median no. of days since symptom 
onset (IQR)¶
8 (5–13) 9 (5–13) 6 (3–10) 9 (5–12) 13 (8–18)
Median no. of days since hospitaliza-
tion (IQR)
2 (1–5) 2 (1–5) 2 (1–6) 2 (1–4) 5 (3–9)
Respiratory support received 
 — no. (%)
No oxygen 501 (24) 1034 (24) 1535 (100) NA NA
Oxygen only 1279 (61) 2604 (60) NA 3883 (100) NA
Invasive mechanical ventilation 324 (15) 683 (16) NA NA 1007 (100)
Previous coexisting disease — no. (%)
Any of the listed conditions 1174 (56) 2417 (56) 911 (59) 2175 (56) 505 (50)
Diabetes 521 (25) 1025 (24) 342 (22) 950 (24) 254 (25)
Heart disease 586 (28) 1171 (27) 519 (34) 1074 (28) 164 (16)
Chronic lung disease 415 (20) 931 (22) 351 (23) 883 (23) 112 (11)
Tuberculosis 6 (<1) 19 (<1) 8 (1) 11 (<1) 6 (1)
HIV infection 12 (1) 20 (<1) 5 (<1) 21 (1) 6 (1)
Severe liver disease‖ 37 (2) 82 (2) 32 (2) 72 (2) 15 (1)
Severe kidney impairment** 166 (8) 358 (8) 119 (8) 253 (7) 152 (15)
SARS-CoV-2 test result — no. (%)
Positive 1865 (89) 3879 (90) 1340 (87) 3433 (88) 971 (96)
Negative 225 (11) 425 (10) 190 (12) 429 (11) 31 (3)
Test result not yet known 14 (1) 17 (<1) 5 (<1) 21 (1) 5 (<1)
*  Plus–minus values are means ±SD. HIV denotes human immunodeficiency virus, IQR interquartile range, NA not applicable, and SARS-
CoV-2 severe acute respiratory syndrome coronavirus 2.
†  There was a significant (P = 0.01) difference in the mean age between patients in the dexamethasone group and those in the usual care 
group, but there were no significant differences between the groups in any other baseline characteristic.
‡  Among the women, 1 in the dexamethasone group and 3 in the usual care group were pregnant.
§  Race or ethnic group was recorded in the patient’s electronic health record.
¶  Data regarding the number of days since symptom onset were missing for 4 patients in the dexamethasone group and 13 patients in the 
usual care group; these patients were excluded from estimates of the median number of days since onset.
‖  Severe liver disease was defined as requiring ongoing specialist care.
**  Severe kidney impairment was defined as an estimated glomerular filtration rate of less than 30 ml per minute per 1.73 m2.
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received hydroxychloroquine, lopinavir–ritona-
vir, or interleukin-6 antagonists during follow-
up (Table S2). After remdesivir became available 
in the United Kingdom on May 26, 2020, the 
drug was administered to 3 patients before ran-
domization and 2 patients during the follow-up 
period (Table S2).
Primary Outcome
Mortality at 28 days was significantly lower in 
the dexamethasone group than in the usual care 
group, with deaths reported in 482 of 2104 pa-
tients (22.9%) and in 1110 of 4321 patients 
(25.7%), respectively (rate ratio, 0.83; 95% confi-
dence interval [CI], 0.75 to 0.93; P<0.001) 
Figure 1. Enrollment, Randomization, and Inclusion in the Primary Analysis.
Completed follow-up forms were available for 2095 of 2104 patients (99.6%) in the dexamethasone group and 4306 
of 4321 patients (99.7%) in the usual care group. The subgroup of patients who later underwent a second random-
ization to tocilizumab versus usual care in the RECOVERY trial included 95 of 2104 patients (4.5%) in the dexameth-
asone group and 276 of 4321 patients (6.4%) in the usual care group. In addition, 14 patients were randomly assigned 
to receive either convalescent plasma or usual care alone (5 [0.2%] in the dexamethasone group and 9 [0.2%] in the 
usual care group).
9355 (83%) Underwent randomization
between dexamethasone and
other treatments
11,303 Patients were recruited
1948 Were excluded (could have >1 reason)
357 (3%) Did not have dexamethasone available
1707 (15%) Were not considered suitable
for randomization to dexamethasone
6425 (57%) Underwent randomization
between dexamethasone and usual
care alone
2930 Were assigned to receive other active
treatment
1183 Were assigned to receive lopinavir–ritonavir
1172 Were assigned to receive hydroxychloroquine
575 Were assigned to receive azithromycin
2104 (100%) Were assigned to receive dexa-
methasone
1996/2095 (95%) Received dexamethasone
4321 (100%) Were assigned to receive usual
care alone
347/4306 (8%) Received dexamethasone
6 (0.1%) Withdrew consent2 (0.1%) Withdrew consent
2104 (100%) Were included in the 28-day
intention-to-treat analysis
4321 (100%) Were included in the 28-day
intention-to-treat analysis
95 (4.5%) Proceeded to second randomization 276 (6.4%) Proceeded to second randomization
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(Fig. 2A). In a prespecified analysis according to 
the level of respiratory support that the patients 
were receiving at randomization, there was a 
trend showing the greatest absolute and pro-
portional benefit among patients who were re-
ceiving invasive mechanical ventilation (11.6 by 
chi-square test for trend) (Fig. 3). In the dexa-
methasone group, the incidence of death was 
lower than that in the usual care group among 
patients receiving invasive mechanical ventila-
tion (29.3% vs. 41.4%; rate ratio, 0.64; 95% CI, 
0.51 to 0.81) and in those receiving oxygen with-
Figure 2. Mortality at 28 Days in All Patients and According to Respiratory Support at Randomization.
Shown are Kaplan–Meier survival curves for 28-day mortality among all the patients in the trial (primary outcome) 
(Panel A) and in three respiratory-support subgroups according to whether the patients were undergoing invasive 
mechanical ventilation (Panel B), receiving oxygen (with or without noninvasive ventilation) and without invasive 
mechanical ventilation (Panel C), or receiving no supplemental oxygen (Panel D) at the time of randomization. The 
Kaplan–Meier curves have not been adjusted for age. The rate ratios have been adjusted for the age of the patients 
in three categories (<70 years, 70 to 79 years, and ≥80 years). Estimates of the rate ratios and 95% confidence inter-
vals in Panels B, C, and D were derived from a single age-adjusted regression model involving an interaction term 
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out invasive mechanical ventilation (23.3% vs. 
26.2%; rate ratio, 0.82; 95% CI, 0.72 to 0.94) 
(Fig. 2B and 2C). However, there was no clear 
effect of dexamethasone among patients who 
were not receiving any respiratory support at 
randomization (17.8% vs. 14.0%; rate ratio, 1.19; 
95% CI, 0.92 to 1.55) (Fig. 2D). The results were 
similar in a post hoc exploratory analysis re-
stricted to the 5744 patients (89.4%) with a 
positive SARS-CoV-2 test result. Likewise, sen-
sitivity analyses without adjustment for age re-
sulted in similar findings (Table S3).
Patients who were receiving invasive mechan-
ical ventilation at randomization were on aver-
age 10 years younger than those not receiving any 
respiratory support and had a history of symp-
toms before randomization for an average of 
7 days longer (Table 1 and Table S4). The age-
adjusted absolute reductions in 28-day mortality 
associated with the use of dexamethasone were 
12.3 percentage points (95% CI, 6.2 to 17.6) 
among the patients who were receiving invasive 
mechanical ventilation and 4.2 percentage points 
(95% CI, 1.4 to 6.7) among those receiving oxy-
gen only.
Patients with a longer duration of symptoms 
(who were more likely to have been receiving 
invasive mechanical ventilation at randomiza-
tion) had a greater mortality benefit in response 
to treatment with dexamethasone. The receipt of 
dexamethasone was associated with a reduction 
in 28-day mortality among those with symptoms 
for more than 7 days but not among those with 
a more recent symptom onset (12.4 by chi-square 
test for trend) (Fig. S1).
Secondary Outcomes
Patients in the dexamethasone group had a 
shorter duration of hospitalization than those in 
the usual care group (median, 12 days vs. 13 days) 
and a greater probability of discharge alive 
within 28 days (rate ratio, 1.10; 95% CI, 1.03 to 
1.17) (Table 2). The greatest effect regarding 
discharge within 28 days was seen among pa-
tients who were receiving invasive mechanical 
ventilation at randomization (11.7 by chi-square 
test for trend) (Fig. S2A and Fig. S3).
Among the patients who were not receiving 
invasive mechanical ventilation at randomiza-
tion, the number of patients who progressed to 
the prespecified composite secondary outcome 
of invasive mechanical ventilation or death was 
lower in the dexamethasone group than in the 
usual care group (risk ratio, 0.93; 95% CI, 0.85 
to 1.01) (Table 2). This effect was greater among 
the patients who were receiving oxygen at ran-
domization (6.3 by chi-square test for trend) 
(Fig. S2B). Other prespecified analyses of the 
effects of dexamethasone on these secondary 
outcomes among different categories of patients 
are shown in Figures S4 and S5.
Other Prespecified Clinical Outcomes
Among patients who were not receiving invasive 
mechanical ventilation at randomization, the risk 
of progression to invasive mechanical ventilation 
Figure 3. Effect of Dexamethasone on 28-Day Mortality, According to Respiratory Support at Randomization.
Shown are subgroup-specific rate ratios for all the patients and for those who were receiving no oxygen, receiving 
oxygen with or without noninvasive ventilation, or undergoing invasive mechanical ventilation at the time of random-
ization. Rate ratios are plotted as squares, with the size of each square proportional to the amount of statistical in-
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was lower in the dexamethasone group than in 
the usual care group (risk ratio, 0.79; 95% CI, 
0.64 to 0.97) (Table 2). Among those who were 
receiving invasive mechanical ventilation at ran-
domization, successful cessation of invasive me-
chanical ventilation was more likely in the dexa-
methasone group than in the usual care group 
(rate ratio, 1.47; 95% CI, 1.20 to 1.78) (Table 2 
and Fig. S6). Among the patients who were not 
receiving renal-replacement therapy (renal dialy-
sis or hemofiltration) at randomization, the num-
ber of patients who received this treatment 
within 28 days was lower in the dexamethasone 
group than in the usual care group (risk ratio, 
0.61; 95% CI, 0.48 to 0.76) (Table 2).
Most deaths were due to Covid-19, and such 
deaths were less frequent in the dexamethasone 
group than in the usual care group (Table S5). 
The incidence of death from other causes was 
similar in the dexamethasone group and the 
usual care group. In the subgroup of patients 
with available data, the incidence of new cardiac 
arrhythmia was similar in the dexamethasone 
group and the usual care group (Table S6). There 
were four reports of a serious adverse reaction 
that was deemed by the investigators to be re-
lated to dexamethasone: two of hyperglycemia, 
one of gastrointestinal hemorrhage, and one of 
psychosis (all recognized adverse effects of glu-
cocorticoids).
Discussion
Our results show that among hospitalized pa-
tients with Covid-19, the use of dexamethasone 
for up to 10 days resulted in lower 28-day mor-
tality than usual care in patients who were re-
ceiving invasive mechanical ventilation at ran-
domization (by 12.3 age-adjusted percentage 
points, a proportional reduction of approximate-
ly one third) and those who were receiving oxy-
gen without invasive mechanical ventilation (by 
4.2 age-adjusted percentage points, a proportional 
reduction of approximately one fifth). However, 






Rate or Risk Ratio 
(95% CI)*
no./total no. of patients (%)
Primary outcome
Death at 28 days 482/2104 (22.9) 1110/4321 (25.7) 0.83 (0.75–0.93)
Secondary outcomes
Discharged from hospital within 28 days 1416/2104 (67.3) 2748/4321 (63.6) 1.10 (1.03–1.17)
Invasive mechanical ventilation or death† 462/1780 (26.0) 1003/3638 (27.6) 0.93 (0.85–1.01)
Invasive mechanical ventilation 110/1780 (6.2) 298/3638 (8.2) 0.79 (0.64–0.97)
Death 387/1780 (21.7) 827/3638 (22.7) 0.93 (0.84–1.03)
Subsidiary clinical outcomes
Use of ventilation‡ 25/501 (5.0) 65/1034 (6.3) 0.84 (0.54–1.32)
Noninvasive ventilation 20/501 (4.0) 57/1034 (5.5) 0.77 (0.47–1.26)
Invasive mechanical ventilation 9/501 (1.8) 19/1034 (1.8) 1.07 (0.49–2.34)
Successful cessation of invasive mechanical ven-
tilation§
160/324 (49.4) 268/683 (39.2) 1.47 (1.20–1.78)
Renal-replacement therapy¶ 89/2034 (4.4) 314/4194 (7.5) 0.61 (0.48–0.76)
*  Rate ratios have been adjusted for age with respect to the outcomes of 28-day mortality, hospital discharge, and successful cessation of 
invasive mechanical ventilation. Risk ratios have been adjusted for age with respect to the outcomes of invasive mechanical ventilation or 
death (and its subcomponents), use of ventilation, and renal-replacement therapy.
†  Excluded from this category are patients who were receiving invasive mechanical ventilation at randomization.
‡  Excluded from this category are patients who were receiving oxygen (since some patients in this category were receiving noninvasive ventila-
tion) or invasive mechanical ventilation at randomization.
§  Excluded from this category are patients who were not receiving invasive mechanical ventilation at randomization.
¶  Excluded from this category are patients who were receiving renal-replacement therapy at randomization.
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there was no evidence that dexamethasone pro-
vided any benefit among patients who were not 
receiving respiratory support at randomization, 
and the results were consistent with possible 
harm in this subgroup. The benefit was also 
clear in patients who were being treated more 
than 7 days after symptom onset, when inflam-
matory lung damage is likely to have been more 
common. A subsequent meta-analysis of seven 
trials of glucocorticoids for critically ill patients 
with Covid-19, including RECOVERY, has con-
firmed the findings of our trial.22 Our results 
also show that among the patients who were 
receiving oxygen, the use of dexamethasone was 
associated with a lower risk of invasive mechan-
ical ventilation or, for those already receiving 
invasive mechanical ventilation, a greater chance 
of successful cessation. In both these groups, 
the use of dexamethasone increased the chance 
of being discharged from the hospital alive 
within 28 days.
The RECOVERY trial was designed to pro-
vide a rapid and robust assessment of the effect 
of readily available potential treatments for 
Covid-19 on 28-day mortality. Approximately 
10% of all hospitalized patients with Covid-19 in 
the United Kingdom were enrolled in the trial, 
and mortality in the usual care group was con-
sistent with the overall case fatality rate for 
hospitalized patients with Covid-19 in the United 
Kingdom at the time that the dexamethasone 
comparison was active.7 Only essential data were 
collected at hospital sites, with additional infor-
mation (including longer-term mortality) ascer-
tained through linkage with routine data sources. 
We did not collect information on physiologic, 
laboratory, or virologic measures. The protocol 
combines the methods that were used in large, 
simple trials of treatments for acute myocardial 
infarction in the 1980s with the opportunities 
provided by digital health care in the 2020s.23-25 
The trial has progressed rapidly, as is essential 
for studies during epidemics.26 The preliminary 
results for dexamethasone were announced on 
June 16, 2020, less than 100 days after the pro-
tocol was first drafted, and were adopted into 
U.K. practice later the same day.27
Glucocorticoids have been widely used in 
syndromes closely related to Covid-19, including 
SARS, Middle East respiratory syndrome (MERS), 
severe influenza, and community-acquired pneu-
monia. However, the evidence to support or 
discourage the use of glucocorticoids under 
these conditions has been weak owing to the 
lack of data from sufficiently powered random-
ized, controlled trials.28-31 In addition, the evi-
dence base has suffered from heterogeneity in 
glucocorticoid doses, medical conditions, and 
disease severity. It is likely that the beneficial 
effect of glucocorticoids in severe viral respira-
tory infections is dependent on the selection of 
the right dose, at the right time, in the right 
patient. High doses may be more harmful than 
helpful, as may such treatment given at a time 
when control of viral replication is paramount 
and inflammation is minimal. Slower clearance 
of viral RNA has been observed in patients with 
SARS, MERS, and influenza who were treated 
with systemic glucocorticoids, but the clinical 
significance of these findings is unknown.29,32,33 
Unlike with SARS, in which viral replication 
peaks in the second week of illness,34 viral shed-
ding in SARS-CoV-2 appears to be higher early 
in the illness and declines thereafter.35-38 The 
greater mortality benefit of dexamethasone in 
patients with Covid-19 who are receiving respira-
tory support and among those recruited after the 
first week of their illness suggests that at that 
stage the disease may be dominated by immuno-
pathological elements, with active viral replica-
tion playing a secondary role. This hypothesis 
would caution against extrapolation of the effect 
of dexamethasone in patients with Covid-19 to 
patients with other viral respiratory diseases with 
a different natural history.
The RECOVERY trial provides evidence that 
treatment with dexamethasone at a dose of 6 mg 
once daily for up to 10 days reduces 28-day mor-
tality in patients with Covid-19 who are receiving 
respiratory support. We found no benefit (and 
the possibility of harm) among patients who did 
not require oxygen. Before the completion of the 
trial, many Covid-19 treatment guidelines stated 
that the use of glucocorticoids was either contra-
indicated or not recommended.18 Dexamethasone 
is on the list of essential medicines of the World 
Health Organization and is readily available 
worldwide at low cost. Guidelines issued by the 
U.K. chief medical officers, the European Medi-
cines Agency, the World Health Organization, 
and the National Institutes of Health in the 
United States have been updated to recommend 
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the use of glucocorticoids in patients hospital-
ized with Covid-19 requiring oxygen with or 
without ventilatory support.27,39,40
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